Pharmacotherapy for Youth Substance Use Disorders: Are We There Yet?

Kevin M. Gray, M.D.

Introduction

Kevin M. Gray, M.D., is Professor and Director of Child and Adolescent Psychiatry at the Medical University of South Carolina.  Dr. Gray has maintained continuous National Institutes of Health (NIH) funding throughout his career, contributing novel advances to treatments for cannabis and tobacco use disorders in adolescents and young adults. Dr. Gray is Co-Chair of the American Academy of Child and Adolescent Psychiatry (AACAP) Substance Use Committee, serves on the Board of Directors of the American Academy of Addiction Psychiatry, and is a standing member of the NIH Interventions to Prevent and Treat Addictions (IPTA) Study Section.  He serves as Chair of the Advisory Committee for the AACAP Physician Scientist Program in Substance Abuse K12 Award program. Within MUSC, Dr. Gray serves as Chair of the MUSC Hospital Credentials Committee and is a member of the Medical Executive Committee. In addition to maintaining an active clinical practice, Dr. Gray is dedicated to MUSC’s educational mission, providing didactic instruction across training programs and mentoring multiple junior faculty, postdoctoral fellows, residents, and students in clinical research.

Learning Objectives

1. Describe the current rates of substance use among adolescents in the United States.
2. Recognize evidence-based pharmacological strategies targeting adolescent substance use disorders
3. Recognize evidence-based pharmacological strategies targeting psychiatric conditions for adolescents with co-occurring substance use disorders

Live webcast available at:  http://videos.mayo.edu/live

1 AMA PRA Category 1 Credit(s)™ hour is offered for watching this Webcast live.  MedHub will be implemented for all post presentation surveys.  Your name and e-mail are not linked to your evaluation. Identifiers are tracked separately for attendance records only.  To document your attendance, please send an email to rstpsychgr@mayo.edu. The badge reader should continue to be utilized for Gonda and Sister Helen Hayes locations.

Credit Statements

·         Mayo Clinic College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. 

·         Mayo Clinic College of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.   

Archived webcast available at: Psychiatry & Psychology Video Library

Industry Acknowledgment (if applicable): None.

Disclosure Summary

As a provider accredited by ACCME, Mayo Clinic College of Medicine (Mayo School of Continuous Professional Development), must ensure balance, independence, objectivity and scientific rigor in its educational activities.   Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity.  Safeguards against commercial bias have been put in place.  Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation.  Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentation.

Listed below are individuals with control of the content of this program who have disclosed…

Relevant financial relationship(s) with industry:  None

 
No relevant financial relationship(s) with industry:
Brian Palmer, M.D., Michael Bostwick, M.D., Karen Grothe, Ph.D., Lois Krahn, M.D., Jarrod Leffler, Ph.D., Larissa Loukianova, M.D., Mary Machulda, Ph.D., Patricia Maus, M.D., Amber Pearson, Jeffrey Staab, M.D., Cosima Swintak, M.D., Kristin Vickers Douglas, Ph.D., Cynthia Harbeck-Weber, Ph.D., Michael Zaccariello, Ph.D., Georgina Rink

Speaker: Kevin  Gray, M.D.

References to off-label usage(s) of pharmaceuticals or instruments in their presentation:
Speaker: Kevin  Gray, M.D. - Manufacturer(s)/Provider(s): Varenicline (Chantix) is made by Pfizer Inc. Atomoxetine (Strattera) is made by Eli Lilly. All others are available via various brand and generic manufacturers.

Product(s)/Device(s): Nicotine patch, nicotine gum, nicotine nasal spray, bupropion SR, bupropion XL, varenicline, cyanimide, disulfiram, acamprosate, naltrexone, buprenorphine, buprenorphine/naloxone, N-acetylcysteine, sertraline, fluoxetine, lithium, pemoline, methylphenidate spheroidal oral drug absorption system, atomoxetine, osmotic-release methylphenidate

Questions regarding this program can be directed to Amber Pearson at Pearson.Amber@mayo.edu.